Cho, Leslie
Dent, Ricardo
Stroes, Erik S.G.
Stein, Evan A.
Sullivan, David
Ruzza, Andrea
Flower, Andrea
Somaratne, Ransi
Rosenson, Robert S.
Article History
First Online: 2 August 2018
Compliance with Ethical Standards
:
: L.C. has conducted research with Amgen and Esperion, has been a consultant for Amgen, and has been an unpaid consultant for Lilly. R.D. is a former employee of Amgen Inc. and a current employee and stockholder of Esperion. E.S.G.S. has received lecture fees for institution from Amgen, Sanofi, Chiesi, Novartis, and Ionis/Akcea. E.A.S. has received consultancy and expert witness fees from Amgen, and consultancy fees from The Medicines Company, AstraZeneca, Moderna, CVS/Caremark, and Gemphire. D.S. has received research support from Amgen, Merck, and Amarin; advisory board fees from Amgen, Merck, Abbott/Mylan, and Sanofi; and modest honoraria for educational programs from Abbott/Mylan and AbbVie. A.R. and R.S. are employees of Amgen and hold Amgen stock/stock options. R.S. is an inventor on at least one pending patent involving evolocumab. A.F. is a contractor for Amgen Inc. R.S.R. has received research support for institution from Akcea, Amgen, AstraZeneca, The Medicines Company, Regeneron, and Sanofi; has served on advisory boards for Akcea, Amgen, CVS Caremark, Regeneron, and Sanofi; has received honoraria from Akcea, Kowa, and Pfizer; and has received royalties from UpToDate, Inc.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.